Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Abildgaard

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|December 13, 1979
The factor VIII abnormality in severe von Willebrand's diseaseT S Zimmerman, C F Abildgaard, D Meyer
Laboratory Animal Science|February 1, 1972
Quantitative coagulation studies in miceC F Abildgaard, J P Lewis, J Harrison
Journal of Applied Physiology|March 1, 1971
Comparative study of blood coagulation in nonhuman primatesC F Abildgaard, J Harrison, C A Johnson
Blood|June 1, 1984
A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID)S Kinoshita, J Harrison, J Lazerson, et al.
The American Journal of the Medical Sciences|March 1, 1984
Lack of von Willebrand factor, factor VIII related antigen and factor VIII coagulant response to human growth hormone infusion in type 2 diabetes mellitusE O Grecu, B M Sheikholislam, C F Abildgaard
Pediatrics|April 1, 1981
Intracranial hemorrhage in children with idiopathic thrombocytopenic purpuraS J Woerner, C F Abildgaard, B N French
Seminars in Hematology|April 1, 1991
The pharmacokinetics of recombinant factor VIII. The rFactor VIII Clinical Trial GroupJ F Harrison, A L Bloom, C F Abildgaard
The New England Journal of Medicine|December 20, 1973
Prevalence of oropharyngeal excreters of leukocyte-transforming agents among a human populationR S Chang, J P Lewis, C F Abildgaard
Blood|December 1, 1980
Anti-inhibitor Coagulant Complex (Autoplex) for treatment of factor VIII inhibitors in hemophiliaC F Abildgaard, J A Penner, E J Watson-Williams
The New England Journal of Medicine|February 18, 1993
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study GroupJ M Lusher, S Arkin, C F Abildgaard, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|December 13, 1979
The factor VIII abnormality in severe von Willebrand's diseaseT S Zimmerman, C F Abildgaard, D Meyer
Laboratory Animal Science|February 1, 1972
Quantitative coagulation studies in miceC F Abildgaard, J P Lewis, J Harrison
Journal of Applied Physiology|March 1, 1971
Comparative study of blood coagulation in nonhuman primatesC F Abildgaard, J Harrison, C A Johnson
Blood|June 1, 1984
A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID)S Kinoshita, J Harrison, J Lazerson, et al.
The American Journal of the Medical Sciences|March 1, 1984
Lack of von Willebrand factor, factor VIII related antigen and factor VIII coagulant response to human growth hormone infusion in type 2 diabetes mellitusE O Grecu, B M Sheikholislam, C F Abildgaard
Pediatrics|April 1, 1981
Intracranial hemorrhage in children with idiopathic thrombocytopenic purpuraS J Woerner, C F Abildgaard, B N French
Seminars in Hematology|April 1, 1991
The pharmacokinetics of recombinant factor VIII. The rFactor VIII Clinical Trial GroupJ F Harrison, A L Bloom, C F Abildgaard
The New England Journal of Medicine|December 20, 1973
Prevalence of oropharyngeal excreters of leukocyte-transforming agents among a human populationR S Chang, J P Lewis, C F Abildgaard
Blood|December 1, 1980
Anti-inhibitor Coagulant Complex (Autoplex) for treatment of factor VIII inhibitors in hemophiliaC F Abildgaard, J A Penner, E J Watson-Williams
The New England Journal of Medicine|February 18, 1993
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study GroupJ M Lusher, S Arkin, C F Abildgaard, et al.
Pageof 5